Ovid Therapeutics Inc. (OVID)
$3.9
Rating:
Recommendation:
Neutral
| Symbol | OVID |
|---|---|
| Price | $3.9 |
| Beta | 1.132 |
| Volume Avg. | 0.17M |
| Market Cap | 275.351M |
| Shares () | - |
| 52 Week Range | 1.405-4.139 |
| 1y Target Est | - |
| DCF Unlevered | OVID DCF -> | |
|---|---|---|
| DCF Levered | OVID LDCF -> | |
| ROE | 1176.15% | Strong Buy |
| ROA | 1092.09% | Strong Buy |
| Operating Margin | - | |
| Debt / Equity | 14.76% | Neutral |
| P/E | -5.42 | Strong Sell |
| P/B | 2.48 | Strong Buy |
Latest OVID news
About
Download (Excel)Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.